ArticleEuropean journal of medical research2025
Potential novel diagnostic biomarkers of atrial fibrillation: four ferroptosis-related genes linking immune infiltration.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtrial fibrillation (AF) is a common atrial arrhythmia in clinic, regulated by the immune system and associated with ferroptosis. We hypothesized that combining the analysis of ferroptosis and immune infiltration in AF will help identify more precise diagnostic biomarkers.
methodsWe analyzed two gene expression omnibus (GEO) data sets (GSE41177 and GSE122188) and extracted characteristic ferroptosis-related genes related to sinus rhythm and AF via bioinformatic analysis. CIBERSORT was used to identify ferroptosis/immune-related genes (FIRGs) in AF. LASSO model analysis was used to identify novel FIRGs. The GSE79768 data set and qRT-PCR were used to validate the FIRGs. ROC curves were then drawn to evaluate the diagnostic power of the FIRGs, and GSEA was used to detect the pathways enriched with the validated FIRGs.
resultsA total of eight FIRGs were identified between the healthy and AF groups through LASSO model analysis. Four FIRGs (ALOX15, SNX5, CA9, and PROK2) were subsequently validated as novel FIRGs with high diagnostic power for AF (AUC = 0.851-0.911). They were enriched mainly in cytokine-cytokine receptor interactions, ascorbate and aldarate metabolism, the nod-like receptor signaling pathway, and the intestinal immune network for IgA production. In addition, ceRNA networks (mRNA-miRNA-lncRNA) such as SNX5-hsa-miR-185-3p-LINC01165 and PROK2-hsa-miR-125b-2-3p-RP11-333E1.2 were constructed. Candidate drugs, such as linoleic acid, which is targeted by ALOX15, and sulfamide, targeted by CA9, were also identified.
conclusionsOur findings reveal the significant ferroptosis/immune-related genes and the potential pathways and biofunctions enriched with these genes in AF and provide new insights for the diagnosis and interference of AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.